FOXP1 controls mesenchymal stem cell commitment and senescence during skeletal aging

Journal of Clinical Investigation

Volumn 127, Issue 4, 2017, Pages 1241-1253

  Li, Hanjun ^a   Liu, Pei ^a   Xu, Shuqin ^a   Li, Yinghua ^b   Dekker, Joseph D ^c   Li, Baojie ^a   Fan, Ying ^d   Zhang, Zhenlin ^d   Hong, Yang ^b   Yang, Gong ^b   Tang, Tingting ^e   Ren, Yongxin ^f   Tucker, Haley O ^c   Yao, Zhengju ^a   Guo, Xizhi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

^f NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CCAAT ENHANCER BINDING PROTEIN BETA; CCAAT ENHANCER BINDING PROTEIN DELTA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; IMMUNOGLOBULIN KAPPA CHAIN; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR FOXP1; TRANSCRIPTION FACTOR FOXP2; UNCLASSIFIED DRUG; CEBPB PROTEIN, HUMAN; CEBPB PROTEIN, MOUSE; CEBPD PROTEIN, HUMAN; CEBPD PROTEIN, MOUSE; FORKHEAD TRANSCRIPTION FACTOR; FOXP1 PROTEIN, HUMAN; FOXP1 PROTEIN, MOUSE; REPRESSOR PROTEIN;

ADIPOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE AGE; BONE MARROW CELL; BONE MASS; CELL DIFFERENTIATION; CELL FATE; CONTROLLED STUDY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OBESITY; OSTEOLYSIS; PREMATURE AGING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INTERACTION; SENESCENCE; SKELETON; TRANSCRIPTION REGULATION; ANIMAL; BONE DEVELOPMENT; CELL AGING; CELL LINE; CYTOLOGY; GENETICS; HUMAN; KNOCKOUT MOUSE; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY;

ADIPOGENESIS; ANIMALS; BONE MARROW CELLS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CCAAT-ENHANCER-BINDING PROTEIN-DELTA; CELL AGING; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; MICE, KNOCKOUT; OSTEOGENESIS; REPRESSOR PROTEINS;

EID: 85018701648     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI89511     Document Type: Article

References (73)

1. Verma S, Rajaratnam JH, Denton J, Hoyland JA, Byers RJ. Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol. 2002;55(9):693-698.
2. Demontiero O, Vidal C, Duque G. Aging and bone loss: new insights for the clinician. Ther Adv Musculoskelet Dis. 2012;4(2):61-76.
3. Chan GK, Duque G. Age-related bone loss: old bone, new facts. Gerontology. 2002;48(2):62-71.
4. Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone. 2003;33(6):919-926.
5. Méndez-Ferrer S, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466(7308):829-834.
6. Ding L, Morrison SJ. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature. 2013;495(7440):231-235.
7. Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell. 2014;15(2):154-168.
8. Rosen CJ, Ackert-Bicknell C, Rodriguez JP, Pino AM. Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. Crit Rev Eukaryot Gene Expr. 2009;19(2):109-124.
9. Chen Q, et al. Fate decision of mesenchymal stem cells: adipocytes or osteoblasts? Cell Death Differ. 2016;23(7):1128-1139.
10. Farmer SR. Transcriptional control of adipocyte formation. Cell Metab. 2006;4(4):263-273.
11. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997;89(5):747-754.
12. Nakashima K, et al. The novel zinc fingercontaining transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002;108(1):17-29.
13. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88(5):593-602.
14. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell. 2007;130(2):223-233.
15. Krishnamurthy J, et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature. 2006;443(7110):453-457.
16. Molofsky AV, et al. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature. 2006;443(7110):448-452.
17. Janzen V, et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature. 2006;443(7110):421-426.
18. Krishnamurthy J, et al. Ink4a/Arf expression is a biomarker of aging. J Clin Invest. 2004;114(9):1299-1307.
19. Gu Z, et al. Upregulation of p16INK4A promotes cellular senescence of bone marrow-derived mesenchymal stem cells from systemic lupus erythematosus patients. Cell Signal. 2012;24(12):2307-2314.
20. Tyner SD, et al. p53 mutant mice that display early ageing-associated phenotypes. Nature. 2002;415(6867):45-53.
21. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999;397(6715):164-168.
22. Cao L, Li W, Kim S, Brodie SG, Deng CX. Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 fulllength isoform. Genes Dev. 2003;17(2):201-213.
23. Varela I, et al. Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature. 2005;437(7058):564-568.
24. Nishino J, Kim I, Chada K, Morrison SJ. Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression. Cell. 2008;135(2):227-239.
25. Baker DJ, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011;479(7372):232-236.
26. Lin SP, Chiu FY, Wang Y, Yen ML, Kao SY, Hung SC. RB maintains quiescence and prevents premature senescence through upregulation of DNMT1 in mesenchymal stromal cells. Stem Cell Reports. 2014;3(6):975-986.
27. Calo E, Quintero-Estades JA, Danielian PS, Nedelcu S, Berman SD, Lees JA. Rb regulates fate choice and lineage commitment in vivo. Nature. 2010;466(7310):1110-1114.
28. Gabut M, et al. An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Cell. 2011;147(1):132-146.
29. Hu H, et al. Foxp1 is an essential transcriptional regulator of B cell development. Nat Immunol. 2006;7(8):819-826.
30. Feng X, Wang H, Takata H, Day TJ, Willen J, Hu H. Transcription factor Foxp1 exerts essential cell-intrinsic regulation of the quiescence of naive T cells. Nat Immunol. 2011;12(6):544-550.
31. Feng X, et al. Foxp1 is an essential transcriptional regulator for the generation of quiescent naive T cells during thymocyte development. Blood. 2010;115(3):510-518.
32. Li S, et al. Foxp1/4 control epithelial cell fate during lung development and regeneration through regulation of anterior gradient 2. Development. 2012;139(14):2500-2509.
33. Wang B, et al. Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. Development. 2004;131(18):4477-4487.
34. Shu W, Lu MM, Zhang Y, Tucker PW, Zhou D, Morrisey EE. Foxp2 and Foxp1 cooperatively regulate lung and esophagus development. Development. 2007;134(10):1991-2000.
35. Li S, et al. Epithelium-generated neuropeptide Y induces smooth muscle contraction to promote airway hyperresponsiveness. J Clin Invest. 2016;126(5):1978-1982.
36. Zhang Y, et al. Foxp1 coordinates cardiomyocyte proliferation through both cell-autonomous and nonautonomous mechanisms. Genes Dev. 2010;24(16):1746-1757.
37. Leishman E, et al. Foxp1 maintains hair follicle stem cell quiescence through regulation of Fgf18. Development. 2013;140(18):3809-3818.
38. Araujo DJ, et al. FoxP1 orchestration of ASDrelevant signaling pathways in the striatum. Genes Dev. 2015;29(20):2081-2096.
39. Adams KL, Rousso DL, Umbach JA, Novitch BG. Foxp1-mediated programming of limbinnervating motor neurons from mouse and human embryonic stem cells. Nat Commun. 2015;6:6778.
40. Zou Y, et al. Forkhead box P1 (FOXP1) transcription factor regulates hepatic glucose homeostasis. J Biol Chem. 2015;290(51):30607-30615.
41. Carr CW, et al. Chiari I malformation, delayed gross motor skills, severe speech delay, and epileptiform discharges in a child with FOXP1 haploinsufficiency. Eur J Hum Genet. 2010;18(11):1216-1220.
42. Wang B, Lin D, Li C, Tucker P. Multiple domains define the expression and regulatory properties of Foxp1 forkhead transcriptional repressors. J Biol Chem. 2003;278(27):24259-24268.
43. Chamberlain AA, et al. DNA methylation is developmentally regulated for genes essential for cardiogenesis. J Am Heart Assoc. 2014;3(3):e000976.
44. Greenbaum A, et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature. 2013;495(7440):227-230.
45. Nakachi Y, et al. Identification of novel PPARgamma target genes by integrated analysis of ChIPon-chip and microarray expression data during adipocyte differentiation. Biochem Biophys Res Commun. 2008;372(2):362-366.
46. Zhong ZA, Zahatnansky J, Snider J, Van Wieren E, Diegel CR, Williams BO. Wntless spatially regulates bone development through ?-catenindependent and independent mechanisms. Dev Dyn. 2015;244(10):1347-1355.
47. Brun RP, Kim JB, Hu E, Altiok S, Spiegelman BM. Adipocyte differentiation: a transcriptional regulatory cascade. Curr Opin Cell Biol. 1996;8(6):826-832.
48. Hilton MJ, et al. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med. 2008;14(3):306-314.
49. Tao J, Chen S, Lee B. Alteration of Notch signaling in skeletal development and disease. Ann N Y Acad Sci. 2010;1192:257-268.
50. Zhang W, et al. Aging stem cells. A Werner syndrome stem cell model unveils heterochromatin alterations as a driver of human aging. Science. 2015;348(6239):1160-1163.
51. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell. 2006;127(2):265-275.
52. Kua HY, et al. c-Abl promotes osteoblast expansion by differentially regulating canonical and non-canonical BMP pathways and p16INK4a expression. Nat Cell Biol. 2012;14(7):727-737.
53. Kubo H, et al. Identification of mesenchymal stem cell (MSC)-transcription factors by microarray and knockdown analyses, and signature molecule-marked MSC in bone marrow by immunohistochemistry. Genes Cells. 2009;14(3):407-424.
54. Benisch P, et al. The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors. PLoS ONE. 2012;7(9):e45142.
55. Jones MJ, Goodman SJ, Kobor MS. DNA methylation and healthy human aging. Aging Cell. 2015;14(6):924-932.
56. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell. 2004;3(6):379-389.
57. Akune T, et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004;113(6):846-855.
58. Ge C, Cawthorn WP, Li Y, Zhao G, Macdougald OA, Franceschi RT. Reciprocal control of osteogenic and adipogenic differentiation by ERK/MAP kinase phosphorylation of Runx2 and PPAR? transcription factors. J Cell Physiol. 2016;231(3):587-596.
59. Sun H, Kim JK, Mortensen R, Mutyaba LP, Hankenson KD, Krebsbach PH. Osteoblast-targeted suppression of PPAR? increases osteogenesis through activation of mTOR signaling. Stem Cells. 2013;31(10):2183-2192.
60. Zhao H, et al. Foxp1/2/4 regulate endochondral ossification as a suppresser complex. Dev Biol. 2015;398(2):242-254.
61. Marie PJ, Kassem M. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endocrinol. 2011;165(1):1-10.
62. Banham AH, et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res. 2001;61(24):8820-8829.
63. Wlodarska I, et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia. 2005;19(8):1299-1305.
64. Fenton JA, et al. t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2006;45(2):164-168.
65. Brown P, Marafioti T, Kusec R, Banham AH. The FOXP1 transcription factor is expressed in the majority of follicular lymphomas but is rarely expressed in classical and lymphocyte predominant Hodgkin's lymphoma. J Mol Histol. 2005;36(4):249-256.
66. Put N, Deeren D, Michaux L, Vandenberghe P. FOXP1 and PAX5 are rare but recurrent translocations partners in acute lymphoblastic leukemia. Cancer Genet. 2011;204(8):462-464.
67. Shigekawa T, et al. FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer. Horm Cancer. 2011;2(5):286-297.
68. Toma MI, et al. Expression of the Forkhead transcription factor FOXP1 is associated with tumor grade and Ki67 expression in clear cell renal cell carcinoma. Cancer Invest. 2011;29(2):123-129.
69. Hu CR, Wang JH, Wang R, Sun Q, Chen LB. Both FOXP1 and p65 expression are adverse risk factors in diffuse large B-cell lymphoma: a retrospective study in China. Acta Histochem. 2013;115(2):137-143.
70. Ijichi N, Ikeda K, Horie-Inoue K, Inoue S. FOXP1 and estrogen signaling in breast cancer. Vitam Horm. 2013;93:203-212.
71. Dekker JD, et al. Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1. Proc Natl Acad Sci USA. 2016;113(5):E577-E586.
72. Logan M, Martin JF, Nagy A, Lobe C, Olson EN, Tabin CJ. Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis. 2002;33(2):77-80.
73. Scheller EL, et al. Use of osmium tetroxide staining with microcomputerized tomography to visualize and quantify bone marrow adipose tissue in vivo. Meth Enzymol. 2014;537:123-139.